GlassScriptPhysician profile
Kayla Mohr
NPI 1992159156
$8,864.63
in general payments reported to CMS, 2019-2025
27 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $410 · 2021: $745 · 2022: $1,259 · 2023: $2,193 · 2024: $2,197 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,215 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,214.69 |
| Education | $235.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,279.85 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,074.54 | 2022-2025 | |
| Abbvie INC. | $1,073.68 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $921.85 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Janssen Biotech, INC. | $811.11 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $722.58 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $597.79 | 2022-2025 | Opzelura |
| Ucb, INC. | $404.74 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $367.67 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $334.83 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $331.11 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $280.44 | 2021-2025 | |
| Galderma Laboratories, L.P. | $220.47 | 2020-2025 | Nemluvio, Dysport |
| Amgen INC. | $82.99 | 2022-2023 | Otezla |
| Kyowa Kirin, INC. | $65.64 | 2023-2025 | Poteligeo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $54.43 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.37 | 2024 | Siliq, Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2023-2024 | Spevigo |
| Springworks Therapeutics, INC. | $32.38 | 2025 | Gomekli |
| Revance Therapeutics, INC. | $21.79 | 2024 | Daxxify |
| Mayne Pharma Commercial LLC | $19.53 | 2022 | |
| Smith+Nephew, INC. | $17.78 | 2023 | Grafix Pl |
| Dermavant Sciences, INC. | $16.69 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $15.89 | 2022 | |
| Allergan, INC. | $15.08 | 2021 | |
| Arcutis Biotherapeutics, INC. | $13.59 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Mohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.